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Bone-marrow-derived endothelial progenitor cells (BM-EPCs) contribute to postnatal neovascularization and therefore are of
great interest for cell therapies to treat ischemic diseases. However, their origin and characteristics are still in controversy. In this
paper, we identiﬁed the origin/lineage of the BM-EPCs that were isolated from bone marrow mononuclear cells and diﬀerentiated
with the induction of bone-marrow endothelial-cellconditioned medium (ECCM). BM-EPCs were characterized in terms of
phenotype, lineage potential, and their functional properties. Endothelial cell colonies derived from BM-EPC were cultured with
ECCM for 3 months. Cultured EPC colony cells expressed endothelial cell markers and formed the capillary-like network in vitro.
EPC colony cells expressed diﬀerential proliferative capacity; some of the colonies exhibited a high proliferative potential (HPP)
capacity up to 20 population doublings. More importantly, these HPP-EPCs expressed hematopoietic marker CD45, exhibited
endocytic activities, and preserved some of the myeloid cell activity. In addition, the HPP-EPCs secrete various growth factors
including VEGF and GM-CSF into the culture medium. The results demonstrate that these EPCs were primarily derived from
hematopoietic origin of early precursor cells and maintained high proliferative potential capacity, a feature with a signiﬁcant
potential in the application of cell therapy in ischemic diseases.
1.Introduction
Bone marrow mononuclear cells (BMMNCs) contain endo-
thelial progenitor cells (EPCs) valuable in cell therapy to
enhance postischemic neovascularization. It has been shown
that BMMNCs, which can be easily prepared from bone
marrow extraction, have dramatic eﬀects in the formation of
neovascularization in ischemic diseases or tumor model [1–
4].InspiteofextensivestudiesonEPC[3,5–7],itisstillquite
challenging to induce all the potential EPCs from BMMNC
or bone marrow into functional EPC due to the following
reasons: (1) hierarchy of hematopoietic progenitors in bone
marrow; (2) EPCs exist as a distinct cell type residing in the
bone marrow stroma; (3) imperfect induction conditions in
vitro. Extensive literature clearly documented the presence
of EPCs in the bone marrow; it is important to elucidate
the origin of the BM-EPC and continuously to improve
strategies for isolating and characterizing the valuable EPC
from BMMNC, thereby ultimately utilizing these EPCs for
therapeutic purposes in ischemic and tumor diseases.
We have established and characterized a BMEC line in
our lab [8]. BMEC-CM derived from the BMEC line culture
enhancedtheproliferationanddiﬀerentiationofhematopoi-
etic progenitors [9–11] and stimulated the proliferation of
EPC [12, 13]. In this paper, we present the in vitro model
for characterization of bone-marrow-derived EPC with the
induction of BMEC-CM. Under this unique condition, a
population of bone-marrow-derived EPC has been enriched
and characterized. Our data demonstrate that these EPCs
were primarily derived from hematopoietic origin of early
precursor cells and maintained high proliferative potential2 Bone Marrow Research
(HPP) capacity, a feature with a signiﬁcant potential in the
application of cell therapy in ischemic diseases.
2. Methods
2.1. Culture of Endothelial Cell Colony. Murine bone mar-
row mononuclear cells (BMMNCs) were prepared. Bone
marrow EC-cols were established using the previously
described method with modiﬁcation [12]. Brieﬂy, one mil-
lion BMMNCs were suspended in DMEM containing 20%
FBS and 20% bone-marrow-endothelial-cell-conditioned
medium (BMEC-CM, see below) and were seeded onto
a ﬁbronectin-coated well of a 24-well tissue plate. After 5
days in culture, cells were trypsinized and replated at low
density of 2 × 104 cells/well (6-well plate) or 10cells/well
( 9 6 - w e l lp l a t e ) .E a c hw e l lo f9 6 - w e l lp l a t eo r6 - w e l lp l a t e
contained 200μl or 2mL DMEM with 20% FBS and 20%
EC-CM, respectively. Cells were cultured at 37◦C, 5% CO2
in a humidiﬁed incubator. Media were changed every week.
Each well was examined for the growth of endothelial cells
every 3 days. In most wells of 96-well plate, one colony was
observed in each well. The wells that contained only one
colony were selected for the study. In the well of 6-well plate,
one big colony (>10,000 cells) was selected and the other
endothelial cells and smaller EC-cols were removed with a
policeman under microscope after 4 weeks in culture. As a
result, only one EC-col was cultured in each well. The cell
number of each colony was counted under microscope or
counted with a hemacytometer.
2.2. Preparation of Bone-Marrow-Endothelial-Cell-Condi-
tioned Medium. The murine bone-marrow-derived endo-
thelial cell line was established in our laboratory [8]. One
hundred thousand immortalized endothelial cells or fresh
cultured EPC-derived cells were cultured in DMEM for
48 hours without serum. The conditioned medium from
endothelial cell line was named BMEC-CM; the conditioned
medium from EPC-derived cells was named EPC-CM. The
conditioned media were collected and kept at −20◦Cb e f o r e
further use.
2.3. Immunoﬂuorescence. Cells from colonies were immun-
ostained with anti-murine CD31 IgG (Sigma), anti-von
Willebrand factor (vWF) IgG (Dako), and anti-CD45 IgG
(Biolegend), respectively, followed by secondary antibodies
conjugated to FITC or Texas-red, using a standard procedure
described previously. To assess lectin binding, biotinylated
Ulex europaeus agglutinin-I (UEA-I) and streptavidin-Alexa
Fluor488wereapplied.Inaddition,cellswereincubatedwith
10ug/mL DiI-Ac-LDL for the uptake of acetylated LDL assay
as described previously [12].
2.4. Proliferative Potentials. Cell numbers of each colony
cultured in the wells of 96-well plate were counted under
microscopestartingfromday7ofcultureandfollowedupfor
30 days. The number of cells per colony cultured in a well of
6-well plate was counted under microscope or with a hema-
cytometereverytwoweeksandfollowedupfor14weeks.The
data were analyzed for the description of the growth curve.
2.5. Vascular Network Formation. Fifty percent BMEC-CM
plus 20% F-CM (ﬁbroblast-cell-conditioned medium) was
added into a well of 6-well plate in which a large colony
has been cultured.Medium wasreplaced each week. Vascular
network formation was monitored every day under an in-
verted microscopy.
2.6. Secreted Growth Factors. To analyze growth factors se-
creted into the culture media, cells derived from EC-cols,
which have been cultured for more than one and half month
in tissue culture incubator, were exposed to serum-free and
growth-factor-freeDMEMFor48hours.Conditioned media
were collected and analyzed for vascular endothelial growth
factor and granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF) by ELISA (R and D system). For evaluation of
the biological activity of the secreted growth factors in the
CM, the serum-free supernatant of EC colony cells (EPC-
CM) was tested in the liquid culture system with variable
concentrations of 0%, 5%, 10%, 20%, and 40%, respectively;
the growth of endothelial cell colony was subsequently
evaluated.
2.7. Endocytosis. Endocytosis assays were performed with
EC-col-derived cells, macrophages, and HUVECs. The
preparation of Candida albicans reagent was by the addi-
tion of Candida albicans to DMEM containing 20% FBS.
Adherent cells derived from the EC colony (45d) in the 96-
well plate were incubated with this solution for 2 hours
in tissue culture incubator. Subsequently, cells were stained
withWright-Giemsa’sstaining.NumbersofCandidaalbicans
internalized by each cell were counted under microscope.
Macrophages and HUVECs were included as positive and
negative controls, respectively, for endocytosis.
2.8. Statistical Analysis. Results were expressed as means±
SD. Levels of signiﬁcance were determined using Student’s
t-test. P values less than 0.05 were considered statistically
signiﬁcant.
3. Results
3.1. Morphology and Phenotype of EC Colony. BMMNCs
were incubated in 20% BMEC-CM for 5 days, this CM-
mediated induction signiﬁcantly promotes the diﬀerentia-
tionoftheBMMNCtowardsEPCasshowninFigure 1.A ft er
the initial 5-day incubation, BMMNCs were replated in a
low-density culture dish in the presence of BMEC-CM. EPC-
derived colonies (EC-cols) were formed with variable sizes of
colonies containing dozens to thousands of cells per colony.
An EPC colony, negative for CD45 and positive for EC
markers, was identiﬁed in experiments of the primary EPC
colony culture (Figure 2(A)). Interestingly, the CD45-EC+Bone Marrow Research 3
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Figure 1: Bone-marrow-derived adherent cells were identiﬁed to be endothelial progenitor cells. After 5-day culture of BMMNCs with
BMEC-CM, adherent cells were replated at low density. A representative of 10-day colony (a), 30-day colony (b), and 60-day colony (c)
was shown, respectively. Round cells or spindle-shaped cells were observed in (a), (b), and (c). These cells were positive for vWF (d) and
CD31(e). (f) is the merge of (d) and (e). Scale bar, 50μm.
(A) (B)
(B1) (B2) (B3)
Figure 2: Bone-marrow-derived endothelial cell colonies. An eighteen-day colony (A) and 35-day colony (B) were shown. Cells from colony
A were negative for CD45 and positive for EC markers (data not shown). Cells from colony B were positive for CD31(B1) and CD45(B2).
(B3) is the merge of (B1) and (B2).
colony was rarely found in the EPC colony culture with
this in vitro condition. CD45-EPC colony can be derived
from either angioblasts or mesenchymal stem cells (MSCs)
in the bone marrow [14, 15]. We might speculate that this
particularCD45-EC+colony(Figure 2(A))wasderivedfrom
angioblast rather than MSC, because MSCs were completely
inhibited by cytokines/growth factors presented in the
BMEC-CM used for EPC colony culture; this has been
demonstrated previously in our lab [12]. In contrast, most
of the EPC colonies generated with this in vitro condition,
regardless of cultures in the plate of 96 wells or 6 wells, were
CD45+ EC+ (Figure 2(B)). Given the fact that EPCs derived4 Bone Marrow Research
from hematopoietic lineage express CD45+, it is thus logical
to propose that the CD45+ bone marrow-derived EPCs are
originated from hematopoietic lineage.
EPCs possess diﬀerential proliferative capacity depend-
ing on the hierarchy of hematopoietic progenitor that they
arederivedfrom.Quantitatively,wehaveobservedthat 671±
93.5 EPCs were derived from 1×106 bone marrow mononu-
clear cells. For example, if the EPC is derived from a myeloid
progenitor or monocyte, this EPC has limited proliferative
capacity, resulting in a small colony [16]. On the contrary,
if the EPC is derived from hematopoietic stem cell or an
undiﬀerentiated early precursor in this lineage, this EPC
has potent proliferative capacity, resulting in a large colony.
The percentage of high proliferative potential EPC colonies
is 1-2% among all the EPC colonies. This discrepancy of
EPC proliferative capacity has also been attributed to the
hierarchy of hematopoietic progenitors in bone marrow
[17]. Next, we designed experiments to evaluate the EPC
proliferation capacity.
3.2. EPC Proliferation. Proliferative capacity of a single
endothelial progenitor cell was evaluated by the colony size.
After 5-day culture of BMMNC with BMEC-CM, cells were
tripsinized and replated for evaluation of their proliferative
capacity. To examine colony size of 30-day culture, cells were
plated at 10cells/well of 96-well plates. At this low cell-
plating density, one colony per well was achieved in most of
the wells of 96-well plates. To examine the high proliferative
potential colony, 2×104 cells/wellof6-wellplatewereplated.
After 4 weeks in culture, one large endothelial cell colony
was selected and allowed to grow in one well (see Section 2).
Eighty-two single cell colonies were formed from wells of 96-
well plate, and 8 high proliferative potential colonies were
observed from 6-well plates. Among the 82 colonies, 72%
of single EPC gave rise to colonies containing cells ranging
from 101 to 1000 cells, 9% ranging from 50–100cells, and
19% ranging from 1001 to 5000 cells or more in a period
of 3 weeks of culture (Figure 3(a)). The cell number/per
colony was (740.97 ± 230.70) × 104 cells in the eight high
proliferative potential colonies in a period of 14 weeks of
culture (Figure 3(b)). Samples of these colony-derived cells
were reexamined for cell markers by immunoﬂuorescence,
theyarepositiveforECmarkersandpositiveforCD45.These
EPCs were expanded for 20 population doublings.
3.3. Angiogenic Capacity of the Colony Cells. EPC colony
cells derived from BMMNC showed capacity of forming
capillary-like network structure in vitro. We have found that
25–37% of EPC colonies have the capacity to form cap-
illary-like structure with appropriate culture condition.
EPC colony cells (45d) formed capillary-like structure
when exposed to 50% BMEC-CM plus 20% F-CM for 2
days (Figure 4(a)). 15 ± 2 capillary-like structures per
20×microscopic ﬁeld were formed. In contrast, the cap-
illary-like structure did not form (0 to 1 capillary-like struc-
ture per ﬁeld) when exposed to VEGF matrigel condition for
the same time points.
3.4. Growth Factors Produced by EPC In Vitro. BMMNC-
derived EPCs were cultured in serum-free and BMEC-CM-
free medium. The cultured medium was harvested after 48-
hour incubation. We evaluated the level of cytokines secreted
by EPC using ELISA assay. Over a 48-hour culture, EPCs
secreted VEGF of 660 ± 95.39pg/106 cells/mL and GM-
CSF of 115.66 ± 18.87pg/106 cells/mL (Figure 5(a)). The
eﬀect of various concentrations of the supernatant (EPC-
CM) on EC-col formation was further analyzed. The EC-
cols were formed in the presence of EPC-CM. There was
ad o s e - d e p e n d e n te ﬀect of EPC-CM on the growth of EC-
cols (Figure 5(b)). In comparison to HUVEC-CM, EPC-CM
showed a stronger stimulation for the formation of EC-cols
(Figure 5(b)).
3.5. Endocytic Capability. A critical feature of monocytes
is the endocytic activity. EPCs derived from CFU-GM or
myeloid lineage maintain strong endocytic activity. We
examined the endocytic capability of EPC-col-derived cells.
EPC-col-derived cells were incubated with Candida albicans,
and the number of the Candida albicans internalized by
each cell was counted. Macrophages and HUVEC were
used as controls. The result showed that cells derived from
EPC-cols internalized signiﬁcantly more Candida albicans
than HUVEC (P<0.001), but less than macrophages
(P<0.01). Monocytes/macrophages are derived from
myeloid lineage and CD45+, exhibiting a strong phagocytic
activity (Figure 6(a)). Conversely, HUVECs are derived from
angioblasts [14] and CD45− [18], exhibiting a weak phago-
cytic activity (Figure 6(c)). In fact, these EPCs maintained
some of the phagocytic feature, one of the critical charac-
teristics of hematopoietic lineage cells. More importantly,
this phagocytic activity demonstrated by these EPCs argues
against the possibility of their angioblast origin.
4. Discussion
In this study, with the induction of BMEC-CM, BMMNC
gave rise to cell colonies that expressed EC markers, in-
corporated Ac-LDL, reacted with endothelial speciﬁc Ulex
europaeus lectin; showed endothelial morphology, exhibited
a high proliferative capacity, and formed capillary-like
structures, all of these indicating they are EPC.
A variety of stem cells/progenitor cells in bone mar-
row can be induced and diﬀerentiated into EPC in vivo
and in vitro. The rare hemangioblasts and their progeny
angioblasts [14, 19–22], the hematopoietic stem cells [23]
and their progeny of myeloid lineage [24–26], and the
multipotent adult progenitor cells and/or MSC [15]a r e
the primary sources to give rise to EPC. In this study, the
growth of MSC from BMMNC was completely inhibited
as described in our previous report [12]. Therefore, the
EPC generated in this report (hereafter termed HS-EPC)
could be originated either from hemangioblasts, angioblasts,
and their progeny, or from hematopoietic stem cells and
their progeny (Figure 7). It is highly unlikely that HS-
EPCs are originated from angioblasts for the following
reasons: (1) the EPCs derived from angioblasts have higherBone Marrow Research 5
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Figure 3:Proliferative capacity assayofbone-marrow-derived EPC.(a)Distributionofdiﬀerentsizes ofEC-colafter21 daysofculture. Each
bar represents the mean±SD of 3 experiments. ∗P<0.05, ∗∗∗P<0.001 in comparison to the group of 50–100 cells. (b) Growth curve of
eight large EC-cols. The number of cells from each colony was counted every 2 weeks for 14 weeks.
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Figure 4: Cells of EPC colony (CD45+ EC+) derived from BMMNCs (a) formed capillary-like network when exposed to 50% EC-CM and
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proliferative capacity relative to HS-EPC. For example, the
cord-blood-derived HPP-EPC could be expanded for at least
100 population doublings and yield 1010 to 1012 cells per
EPC after 90-day incubation [27]. HUVECs and HAECs
derived from angioblasts can be passaged for at least 40
population doublings in vitro [18]. In contrast, HS-EPC
can be expanded for 20 population doublings and yield
7 ×106 cellsperEPCafter14-weekincubation(Figure 3(b)).
(2) EPC derived from angioblasts responded well to VEGF;
VEGF is a potent stimulator for the formation of capillary-
like structure for EPC derived from angioblasts [27]. On
the contrary, HS-EPC responded poorly to VEGF in the
formation of capillary-like structure (Figure 4). Moreover,
EC-CMs or F-CMs rather than VEGF were more potent
stimulators for the formation of capillary-like structures on
HS-EPC cells (Figure 4). (3) Cells derived from angioblasts6 Bone Marrow Research
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Figure 5: Analysis of cytokines in EPC-CM. The culture media of EPC colonies were collected after 48-hour incubation in serum-free
condition. (a) Concentrations of cytokines in supernatant were measured by ELISA. (b) Ten thousand cells were cultured in wells of 24-well
plate with EPC-CM (closed circle) or HUVEC-CM (open circle) of the following concentrations: 0%, 5%, 10%, 20%, and 40%, respectively.
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Figure 6: Endocytosis assay. The number of Candida albican internalized by each cell was counted under microscope. (a) Macrophages (b)
Cells from BMMNC-derived EPC-cols. (c) HUVEC. (d) The number of internalized Candida albicans per cell was shown for each cell type.
Bars represent mean±SD of the number of candida albicanin in each type of the cells of three experiments. MA: macrophages. BMEC:
bone marrow endothelial cells from EPC-colony (45d). HUVEC: human umbilical vein endothelial cells. ##P<0.01 (BMEC versus MA),
∗∗∗P<0.001 (BMEC versus HUVEC).Bone Marrow Research 7
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Figure 7: A diagram showing a diﬀerentiation pathway for HS-EPC derived from bone marrow origin. The hematopoietic stem/progenitor
cells were selectively adhered to the culture plates and proliferated/diﬀerentiated in the presence of BMEC-CM in vitro. EPCs generated
in this in vitro model most likely are originated from hematopoietic stem cells or their early progenitors rather than from angioblsts or
mesenchymal stem cells. HS-EPC: hematopoietic stem cell or early-hematopoietic-progenitor-cell-derived EPC.
showed a weak phagocytic capability (Figure 6, HUVEC),
but HS-EPC exhibited a signiﬁcantly higher phagocytic abil-
ity than HUVEC (angioblast progeny. (4) EPCs derived from
angioblasts or MSC were negative for CD45, whereas HS-
EPCs were positive for CD45 (Figure 2(b)). It is most likely
that HS-EPCs are originated from hematopoietic stem cells
and their early progeny (Figure 7). It has been reported that
the hematopoietic stem cells and their progeny of myeloid
lineage have been induced to diﬀerentiate into endothelial
cells [2, 16, 23, 24, 28]. Pleiotrophin might induce trans-
diﬀerentiation of monocytes into functional endothelial
cells [29]; likewise, TNFα also signiﬁcantly facilitates the
endothelial diﬀerentiation of myeloid cells in vitro and in
vivo[30]. Madlambayan et al. [31] demonstrate that myeloid
progenitor cells directly participate in new blood vessel
formationinresponsetoSDF-1α.Theyreportthatsecondary
transplantation of single hematopoietic stem cells showed
that HSCs are a long-term source for neovasculogenesis.
Our experiments provide evidence that hematopoietic cells
can diﬀerentiate into endothelium in a liquid culture with
EC-CM. We believe that EC-CM contains various factors
including VEGF, SDF-1, and TNF-α and unknown factors
thatplayasynergismeﬀectintheinductionofhematopoietic
cells to endothelial cells.
A common feature of EPC derived from myeloid lin-
age and monocytes is their limited proliferative capacity
[16, 32]. Interestingly, HS-EPC, positive for CD45, exhibited
much higher capacity for proliferation in comparison to
EPC derived from myeloid linage cells; for example, one
HS-EPC yields about 7 × 106 EC (Figure 3(b)), only
hematopoietic-stem-cell-/early-progenitor-originated and
diﬀerentiated endothelia lineage cells can possess such high
proliferative capacity. This high proliferative capacity is
indeed the characteristic of stem/precursor cell of hem-
atopoietic lineage. We believe that the various cytokines and
unidentiﬁed molecules secreted by the BMEC line (used
for the preparation of BMEC-CM) [9] and their synergistic
eﬀects played a signiﬁcant role in promoting the adherence
of hematopoietic stem cells in the initial BMMNC culture;
moreover, these factors not only facilitate the survivor,
proliferation, and diﬀerentiation of stem cell/progenitor, but
also induce stem cells to diﬀerentiate towards EPC lineage
and stimulate their proliferation [12, 13]. The secreted fac-
tors/moleculespreservedthecharacteristicsofhematopoietic
stem cells during the diﬀerentiation towards EPC, such as
high capacity of proliferation. Thus, one hematopoietic stem
cell or progenitor cell can result in million of endothelial
cells under the induction of BMEC-EM. This phenotype
is extremely important given their potential in repair in
ischemic diseases. For example, a recent study showed that
after intracoronary transplantation of bone marrow cells
enriched in CD34/CD45+ and CD133/CD45+, patients with
ischemic heart disease showed a signiﬁcantly reduced size of
infract area and an increased global ejection fraction as well
as infract wall movement velocity [33]. Our study provides
increasingly important insight for the treatment of ischemic
disease by using HS-EPC. This method for isolating EPC
is quite unique because it induced the early hematopoietic
stem cells rather than late diﬀerentiated progenitors; thus,
the high proliferative potential capacity is a trademark of this
in vitro isolation technique, a critical feature in translational
research in ischemic diseases. To further categorize the
speciﬁc cell markers expressed on the HS-EPC is important
for the sorting of this unique population of EPC.
In this paper, we present an in vitro model of cell
diﬀerentiation from hematopoietic stem/progenitor cells
in BMMNC to endothelial linage. Given the advantage of
easy access of bone marrow tissue and negative immune
rejection by using self-bone-marrow cells, HS-EPC would
be an important source for cell therapy in ischemic diseases.
It is thus important to further elucidate the mechanisms of
hematopoietic stem cell diﬀerentiation to endothelial linage.
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